Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia

[1]  G. Blasi,et al.  Rasd2 Modulates Prefronto-Striatal Phenotypes in Humans and ‘Schizophrenia-Like Behaviors’ in Mice , 2016, Neuropsychopharmacology.

[2]  M. Morari,et al.  Eltoprazine prevents levodopa‐induced dyskinesias by reducing striatal glutamate and direct pathway activity , 2015, Movement disorders : official journal of the Movement Disorder Society.

[3]  Gilberto Fisone,et al.  Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease , 2015, Progress in Neurobiology.

[4]  B. Picconi,et al.  Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion , 2015, Scientific Reports.

[5]  A. Pisani,et al.  Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons , 2015, Neurobiology of Disease.

[6]  M. Morari,et al.  Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia , 2015, Annals of clinical and translational neurology.

[7]  B. Davidson,et al.  Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes , 2015, Neuron.

[8]  S. Snyder,et al.  Rhes Deletion Is Neuroprotective in the 3-Nitropropionic Acid Model of Huntington's Disease , 2013, The Journal of Neuroscience.

[9]  P. Calabresi,et al.  Nociceptin/Orphanin FQ Receptor Agonists Attenuate l-DOPA-Induced Dyskinesias , 2012, The Journal of Neuroscience.

[10]  J. Swann,et al.  Multiple Roles for Mammalian Target of Rapamycin Signaling in Both Glutamatergic and GABAergic Synaptic Transmission , 2012, The Journal of Neuroscience.

[11]  P. Greengard,et al.  Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism* , 2012, The Journal of Biological Chemistry.

[12]  L. Harrison.  Rhes: A GTP-Binding Protein Integral to Striatal Physiology and Pathology , 2012, Cellular and Molecular Neurobiology.

[13]  M. Cenci,et al.  Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease , 2012, Progress in Neurobiology.

[14]  M. Cenci,et al.  In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels , 2012, Neurobiology of Disease.

[15]  S. Snyder,et al.  Rhes, a striatal–enriched small G–protein, mediates mTOR signaling and L–DOPA–induced dyskinesia , 2011, Nature Neuroscience.

[16]  G. Fisone,et al.  L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission , 2011, Front. Behav. Neurosci..

[17]  K. Dupre,et al.  Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation , 2011, Neuropharmacology.

[18]  M. Morari,et al.  Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels , 2011, Journal of neurochemistry.

[19]  S. Snyder,et al.  Huntington’s Disease is a disorder of the corpus striatum: Focus on Rhes (Ras homologue enriched in the striatum) , 2011, Neuropharmacology.

[20]  L. Harrison,et al.  Rhes and AGS1/Dexras1 affect signaling by dopamine D1 receptors through adenylyl cyclase , 2011, Journal of neuroscience research.

[21]  L. Savage,et al.  Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats , 2011, Experimental Neurology.

[22]  Alexander Hammers,et al.  Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.

[23]  D. Erlij,et al.  l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata , 2011, Neurobiology of Disease.

[24]  Erwan Bezard,et al.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa–induced dyskinesia , 2010, Proceedings of the National Academy of Sciences.

[25]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[26]  Paul Greengard,et al.  Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors , 2010, Proceedings of the National Academy of Sciences.

[27]  G. Fisone,et al.  HDAC inhibitors conquer polycomb proteins , 2010 .

[28]  S. Snyder,et al.  Rhes, a Physiologic Regulator of Sumoylation, Enhances Cross-sumoylation between the Basic Sumoylation Enzymes E1 and Ubc9* , 2010, The Journal of Biological Chemistry.

[29]  R. Moratalla,et al.  Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation , 2009, Biological Psychiatry.

[30]  P. Greengard,et al.  Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia , 2009, Science Signaling.

[31]  S. Snyder,et al.  Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity , 2009, Science.

[32]  N. Sonenberg,et al.  Translational Control of Long-Lasting Synaptic Plasticity and Memory , 2009, Neuron.

[33]  G. Lahoste,et al.  Ontogeny and dopaminergic regulation in brain of Ras homolog enriched in striatum (Rhes) , 2008, Brain Research.

[34]  Riccardo Viaro,et al.  Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism , 2008, Neurobiology of Disease.

[35]  Gilberto Fisone,et al.  Parkinson's disease: Levodopa‐induced dyskinesia and signal transduction , 2008, The FEBS journal.

[36]  D. Centonze,et al.  The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons , 2008, Molecular and Cellular Neuroscience.

[37]  M. Cenci,et al.  Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice , 2007, Current protocols in neuroscience.

[38]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[39]  W. Danysz,et al.  Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.

[40]  Riccardo Viaro,et al.  The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and l-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic Pathway , 2007, The Journal of Neuroscience.

[41]  G. Lahoste,et al.  Rhes, the Ras homolog enriched in striatum, is reduced under conditions of dopamine supersensitivity , 2006, Neuroscience.

[42]  N. Pavón,et al.  ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, Biological Psychiatry.

[43]  S. Salvadori,et al.  Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease , 2005, The Journal of Neuroscience.

[44]  P. Mithbaokar,et al.  Rhes Is Involved in Striatal Function , 2004, Molecular and Cellular Biology.

[45]  H. Lindgren,et al.  A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function , 2004, Neurobiology of Disease.

[46]  A. Valencia,et al.  The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors , 2004, Oncogene.

[47]  P. Vargiu,et al.  Thyroid hormone regulation of rhes, a novel Ras homolog gene expressed in the striatum. , 2001, Brain research. Molecular brain research.

[48]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[49]  J. Sutcliffe,et al.  Rhes: A striatal‐specific Ras homolog related to Dexras1 , 1999, Journal of neuroscience research.

[50]  J. Bargas,et al.  Cholinergic Modulation of Neostriatal Output: a Functional Antagonism between Different Types of Muscarinic Receptors Materials and Methods , 1999 .

[51]  J. Labandeira-Garcia,et al.  An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. , 1997, Brain research. Brain research protocols.

[52]  P. Greengard,et al.  Bidirectional Regulation of DARPP-32 Phosphorylation by Dopamine , 1997, The Journal of Neuroscience.

[53]  A. Dopazo,et al.  Isolation of clones of rat striatum-specific mRNAs by directional tag PCR subtraction , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  M. Giordano,et al.  The catalepsy test: its ups and downs. , 1988, Behavioral neuroscience.

[55]  A. Björklund,et al.  mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. , 2013, Journal of Parkinson's disease.